We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

More Complete Genetic Screening Benefits Cardiovascular Disease Patients

By LabMedica International staff writers
Posted on 17 Aug 2021
Print article
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium (Photo courtesy of [U.S.] Centers for Disease Control and Prevention)
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium (Photo courtesy of [U.S.] Centers for Disease Control and Prevention)
Results of a pilot study suggested that information obtained by comprehensive genetic testing would benefit treatment of patients suffering from a wide range of cardiovascular diseases.

Investigators at Baylor College of Medicine (Houston, TX, USA) reported creating a “HeartCare” panel that provided DNA sequences for 158 genes associated with medically actionable cardiovascular conditions along with a genetic risk score for developing cardiovascular disease and genetic data on drug interactions.

The HeartCare panel was used as the basis for assessing 709 individuals from cardiology clinics at Baylor College of Medicine. Samples were analyzed in a CAP/CLIA-certified laboratory, and results were returned to the ordering physician and uploaded to the electronic medical record.

Results revealed that 32% of participants received genetic information that impacted their clinical management. Of those participants, 11% were referred to a genetic specialist for further care. Out of all participants, 9% had an inherited pathogenic gene mutation associated with cardiovascular diseases such as cardiomyopathy and high cholesterol, and 9% had a high overall genetic risk score for developing cardiovascular disease. Among surveyed physicians, 84% reported initiating medical management changes based on these results, including specialist referrals, cardiac tests, and medication changes.

"This study shows that a large proportion of individuals in select ambulatory care clinics can benefit from genetic data," said senior author Dr. Richard Gibbs, professor of molecular and human genetics at Baylor College of Medicine. "There is tangible follow-up care for people who received a positive result, and in many cases for their family members."

The study was published in the August 6, 2021, online edition of the journal Genetics in Medicine.

Related Links:
Baylor College of Medicine


New
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
New
Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
New
Silver Supplier
Lipid Profile Analyzer
Cholestech LDX
New
Neonatal Analyzer
CareStart S1 Analyzer

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.